Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
暂无分享,去创建一个
C. Wilson | C. Boni | F. D. De Braud | A. Figer | J. Cassidy | A. Bonetti | A. de Gramont | A. Gramont | A. Cervantes | F. Braud | C. Louvet | M. Seymour | A Figer | A Cervantes | A Bonetti | G Freyer | D. Papamichael | M. Homerin | A. Hmissi | H. Cortés-Funes | G. Freyer | N. Le bail | D. Hendler | F. Morvan | D Papamichael | A de Gramont | M Seymour | M Homerin | A Hmissi | J Cassidy | C Boni | H Cortes-Funes | N Le Bail | C Louvet | D Hendler | F de Braud | C Wilson | F Morvan | N. Bail | A. de Gramont | Corrado Boni | Andrés Cervantes | N. Le Bail | F. De Braud | Colin H Wilson | Francois Morvan | Colin H Wilson | H. Cortés-Funes | A. Bonetti | A. Figer | M. Seymour | A. Cervantes | D. Papamichael | C. Wilson
[1] N L Geller,et al. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. , 1987, Biometrics.
[2] W. Hiddemann,et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Collier,et al. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[5] E. Raymond,et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers , 1997, Anti-cancer drugs.
[6] S. Barni,et al. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Laurie,et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[9] D. Kerr,et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] P. Piedbois. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Tournigand,et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.
[12] C. Tournigand,et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] L. Collette,et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[15] S. Iacobelli,et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.
[16] F. Lévi,et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.
[17] M. Ychou,et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[19] Michael J. Campbell,et al. Statistical tables for the design of clinical trials , 1987 .
[20] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Kerr,et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Labianca,et al. Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. , 1988, European journal of cancer & clinical oncology.
[23] W. Scheithauer,et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[25] J. Lotz,et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.
[26] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Labianca,et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] M. Ychou,et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] F. Lévi,et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.
[30] D. Cox. Regression Models and Life-Tables , 1972 .
[31] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[32] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[33] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[34] L. Påhlman,et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer , 1994, Cancer.